Humalog (Insulin Lispro)

Humalog is indicated for the management of blood glucose in adults and children with diabetes when rapid insulin action is required.

• Type 1 diabetes mellitus, as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus, when oral agents and basal insulin do not achieve target glycaemia.
• Control of post‑prandial glucose spikes after meals.
• Use in insulin pump therapy (continuous subcutaneous insulin infusion).
• Adjustment of insulin dose during illness or stress under medical supervision.

• Insulin lispro is a recombinant human insulin analog in which two amino acids are reversed, reducing self‑association and allowing rapid dissociation after injection. The molecule binds to the α‑subunit of the insulin receptor on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase. This triggers downstream signaling (PI3‑K/Akt pathway) that promotes translocation of GLUT‑4 transporters, enhances glycogen synthesis, and suppresses hepatic glucose production, resulting in a swift decline in plasma glucose.

Like other rapid‑acting insulins, Humalog may be associated with a range of adverse reactions, most of which are mild and transient, while a few require prompt medical attention.

Common

• Hypoglycemia (low blood glucose), especially if meals are delayed or doses are excessive.
• Injection‑site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Lipodystrophy (localized fat tissue changes) at repeated injection sites.
• Mild nausea or abdominal discomfort.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Hypersensitivity leading to bronchospasm or respiratory distress.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.

When using Humalog, clinicians and patients should observe several precautions to minimize risks and ensure optimal glycemic control.

• Monitor blood glucose frequently, especially before meals, after dosing, and during illness.
• Adjust dose based on carbohydrate intake, physical activity, and renal or hepatic function.
• Avoid injecting into scarred, inflamed, or lipohypertrophic tissue to reduce absorption variability.
• Pregnant or breastfeeding individuals should consult a healthcare provider, as safety data are limited.
• Patients with a history of severe hypoglycemia or unawareness require individualized dosing strategies.
• Store the product according to label instructions; discard after the recommended in‑use period.

Humalog can interact with other medicines or substances that affect glucose metabolism, insulin sensitivity, or absorption, requiring dose adjustments or monitoring.

Avoid

• Concurrent use of other rapid‑acting insulins or high‑dose insulin mixtures without medical supervision.
• Co‑administration of sulfonylureas or meglitinides that increase hypoglycemia risk.
• Use of glucagon‑like peptide‑1 (GLP‑1) receptor agonists without adjusting insulin dose.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can raise blood glucose and necessitate higher insulin doses.
• Alcohol consumption, especially in excess, as it can cause delayed hypoglycemia.
• Thyroid hormones or thyroid replacement therapy, which may alter insulin requirements.